Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

80.65B

Market cap80.65B

Price-Earnings ratio

19.60

Price-Earnings ratio19.60

Dividend yield

0.47%

Dividend yield0.47%

Average volume

634.42K

Average volume634.42K

High today

$800.48

High today$800.48

Low today

$781.05

Low today$781.05

Open price

$800.48

Open price$800.48

Volume

153.08K

Volume153.08K

52 Week high

$859.34

52 Week high$859.34

52 Week low

$541.00

52 Week low$541.00

Stock Snapshot

With a market cap of 80.65B, Regeneron(REGN) trades at $783.32. The stock has a price-to-earnings ratio of 19.60 and currently yields dividends of 0.47%.

As of 2026-09-11, Regeneron(REGN) stock has fluctuated between $781.05 and $800.48. The current price stands at $783.32, placing the stock +0.3% above today's low and -2.1% off the high.

Regeneron(REGN) shares are trading with a volume of 153.08K, against a daily average of 634.42K.

In the last year, Regeneron(REGN) shares hit a 52-week high of $859.34 and a 52-week low of $541.00.

REGN News

TipRanks 2h

Regeneron and Sanofi Complete Key Dupilumab Itch Study, Expanding Dermatology Upside

Regeneron Pharmaceuticals (REGN), Sanofi (SNYNF) announced an update on their ongoing clinical study. Regeneron (REGN) and Sanofi (SNYNF) have completed a Phas...

Simply Wall St 8h

Why Is Regeneron Pharmaceuticals Facing A New Investor Lawsuit? - simplywall.st

...

TipRanks 1d

Regeneron price target raised to $920 from $800 at HSBC

HSBC analyst Rajesh Kumar raised the firm’s price target on Regeneron (REGN) to $920 from $800 and keeps a Buy rating on the shares. The firm adjusted targets i...

Analyst ratings

60%

of 30 ratings

Buy

60%

Hold

33.3%

Sell

6.7%

More REGN News

24/7 Wall St. 3d

Big Short Billionaire Goes Long: Michael Burry Avoids AI, Bets on Beaten own Stocks Instead

Investing Big Short Billionaire Goes Long: Michael Burry Avoids AI, Bets on Beaten own Stocks Instead Michael Burry, the Scion Asset Management founder made fam...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.